Previous 10 | Next 10 |
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Paycheck Protection Program (“PPP”). The PPP, established as par...
SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has shifted part of its production to provide medical-grade hand sanitizers to hospitals and health...
SAN DIEGO, March 30, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals,...
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximatel...
Adamis Pharmaceuticals ( ADMP ) has been fairly quiet since the company received ZIMHI's Complete Response Letter "CRL" from the FDA back on November 22th. ZIMHI is the company's high-dose naloxone injection candidate as a rescue treatment of opioid overdose. Prior to February 19th, the comp...
Based on a recent meeting with the FDA, Adamis Pharmaceuticals ( ADMP -13% ) believes that it can generate the necessary data to support the resubmission of its marketing application next quarter for opioid overdose med Zimhi (high-dose naloxone injection). More news on: Adamis Pharmac...
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission process. On November 22, 2019, Adamis received a Complete Response Letter (CRL...
SAN DIEGO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission process. On November 22, 2019, the company received a Complete Response Letter...
Ultra-thinly traded nano cap BioCorRx ( OTCQB:BICX +7.7% ) is up, albeit on only 700 shares, in reaction to encouraging preclinical data on VDM-001, its candidate for the reversal of opioid overdose that it says is an alternative to naloxone. More news on: BioCorRx Inc., Aurobindo Phar...
Adamis Pharmaceuticals ( ADMP ) received a Complete Response Letter from the FDA in regards to the company's ZIMHI product candidate. Following the press release, the share price was decimated and is now trading around $0.60 a share. This leaves ADMP with a tough decision about how they are ...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...